STIOLTO: payments to doctors
Payments that named STIOLTO as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $236K
- Providers
- 1,170
- Transactions
- 2,230
- Average per transaction
- $106
The per-transaction average — $106 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 1,170 providers the average total is $202, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Boehringer Ingelheim | $116,040 | 49.1% |
| Boehringer Ingelheim International GmbH | $67,196 | 28.5% |
| Boehringer Ingelheim Taiwan Ltd. | $22,243 | 9.4% |
| Boehringer Ingelheim Do Brasil Quimica E Farmaceutical Ltda. | $16,306 | 6.9% |
| Boehringer Ingelheim RCV GmbH & Co KG | $13,874 | 5.9% |
| Boehringer Ingelheim (china) Investment Co., Ltd. | $488 | 0.2% |